ZIONA, Israel, Aug. 2 /PRNewswire-FirstCall/ — PROLOR Biotech, Inc. , a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone linked to PROLOR’s carboxyl terminal peptide technology has significantly increased half-life and bioactivity …
Categories
- Andropause
- Anti-Aging Medicine
- Biotechnology
- Endocrinology
- Exercise And Fitness
- Gene therapy
- HCG Therapy
- Hormone Replacement Therapy
- Infertility
- Integrative Medicine
- Longevity
- Longevity Medicine
- Menopause Management
- Nutraceuticals
- Nutrition
- Preventative Medicine
- Regenerative Medicine
- Sexual Dysfunction
- Stem Cell Therapy
- Testosterone
- Weight Management
Archives